​

Monte Rosa Therapeutics (GLUE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

GLUE Stock Forecast

Monte Rosa Therapeutics (GLUE) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $31.75, with a high of $37.00 and a low of $22.00. This represents a 65.80% increase from the last price of $19.15.

- $8 $16 $24 $32 $40 High: $37 Avg: $31.75 Low: $22 Last Closed Price: $19.15

GLUE Stock Rating

Monte Rosa Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (77.78%), 2 Hold (22.22%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 2 7 Strong Sell Sell Hold Buy Strong Buy

GLUE Price Target Upside V Benchmarks

TypeNameUpside
StockMonte Rosa Therapeutics65.80%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$29.80
Last Closing Price$19.15$19.15$19.15
Upside/Downside--55.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2626---8
Mar, 2626---8
Feb, 2626---8
Jan, 2626---8
Dec, 25251--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 14, 2026Piper Sandler$37.00$23.9954.23%93.21%
Jan 07, 2026Jefferies$31.00$23.2933.10%61.88%
Jan 07, 2026Wedbush$37.00$24.3152.20%93.21%
Dec 17, 2025Kelly ShiJefferies$22.00$18.6617.90%14.88%
Dec 16, 2025Wells Fargo$22.00$16.4533.74%14.88%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 14, 2026Piper SandlerOverweightOverweighthold
Jan 07, 2026JefferiesBuyBuyhold
Jan 07, 2026Cowen & Co.BuyBuyhold
Jan 07, 2026WedbushOutperformOutperformhold
Dec 17, 2025JefferiesBuyBuyhold
Dec 16, 2025Wells FargoOverweightOverweightupgrade
Oct 28, 2024Cowen & Co.BuyBuyhold
Oct 28, 2024Piper SandlerOverweightOverweighthold
Aug 12, 2024Wells FargoOverweightOverweighthold
Jun 28, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.63$-0.98----
Avg Forecast$-2.40$-1.01$-1.55$-1.95$-1.87$-0.51
High Forecast$-2.09$-0.97$-0.96$-0.98$-0.31$-0.11
Low Forecast$-2.55$-1.07$-2.05$-3.67$-3.57$-0.87
Surprise %9.58%-2.97%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$75.62M$123.67M---
Avg Forecast$3.53M$66.18M$24.18M$25.96M$86.61M$253.19M
High Forecast$5.49M$82.03M$37.66M$26.74M$134.90M$394.36M
Low Forecast$1.41M$47.62M$9.68M$25.18M$34.68M$101.38M
Surprise %-14.26%411.44%---

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-135.35M$-72.70M$-38.63M---
Avg Forecast$-119.20M$-52.24M$-77.46M$-179.28M$-99.78M$-26.04M
High Forecast$-107.23M$-49.64M$-49.57M$-50.50M$-16.17M$-5.74M
Low Forecast$-131.17M$-54.84M$-105.34M$-188.47M$-183.39M$-44.92M
Surprise %13.55%39.17%-50.13%---

GLUE Forecast FAQ

Is Monte Rosa Therapeutics stock a buy?

Monte Rosa Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Monte Rosa Therapeutics is a favorable investment for most analysts.

What is Monte Rosa Therapeutics's price target?

Monte Rosa Therapeutics's price target, set by 9 Wall Street analysts, averages $31.75 over the next 12 months. The price target range spans from $22 at the low end to $37 at the high end, suggesting a potential 65.80% change from the previous closing price of $19.15.

How does Monte Rosa Therapeutics stock forecast compare to its benchmarks?

Monte Rosa Therapeutics's stock forecast shows a 65.80% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Monte Rosa Therapeutics over the past three months?

  • April 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Monte Rosa Therapeutics’s EPS forecast?

Monte Rosa Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.95, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-1.87 in 2027, and $-0.51 in 2028.

What is Monte Rosa Therapeutics’s revenue forecast?

Monte Rosa Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $25.96M, reflecting a -79.01% decrease from the reported $123.67M in 2025. The forecast for 2027 is $86.61M, and $253.19M for 2028.

What is Monte Rosa Therapeutics’s net income forecast?

Monte Rosa Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-179M, representing an 364.14% increase from the reported $-38.626M in 2025. Projections indicate $-99.779M in 2027, and $-26.041M in 2028.